Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) [Yahoo! Finance]
Edgewise Therapeutics, Inc. (EWTX)
Company Research
Source: Yahoo! Finance
– Four-week treatment with EDG-7500 demonstrated substantial improvements in measures of feel and function, reductions in key cardiac biomarkers and positive trends in measures of diastolic function – – EDG-7500 was generally well-tolerated; clinical activity was observed without meaningful changes in LVEF, including no participant with a value below 50% – BOULDER, Colo. April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive HCM. EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM without impacting systolic function. CIRRUS-HCM is a multi-part, open-label trial of EDG-7500 in individuals with HCM. In September 2024 , the Company announ
Show less
Read more
Impact Snapshot
Event Time:
EWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EWTX alerts
High impacting Edgewise Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
EWTX
News
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR Newswire
- Edgewise Therapeutics (NASDAQ:EWTX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=EWTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of DirectorsPR Newswire
- Will Edgewise Therapeutics' (EWTX) New CFO Mark a Shift in Its Commercial Strategy? [Yahoo! Finance]Yahoo! Finance
EWTX
Earnings
- 11/6/25 - Beat
EWTX
Sec Filings
- 11/24/25 - Form 4
- 11/24/25 - Form 3
- 11/20/25 - Form 8-K
- EWTX's page on the SEC website